BOSTON, Mass. ( TheStreet) -- A calendar of important, potentially stock-moving biotech events for February:

Feb 1:
Discovery Labs ( DSCO): Surfaxin regulatory update conference call.
Earnings: Biogen Idec ( BIIB), Pfizer ( PFE).

Feb. 2
Earnings: Sangamo BioSciences ( SGMO), Viropharma ( VPHM).

Feb 3:
Alimera Sciences ( ALIM): 36-month results from phase III study of Iluvien in diabetic macular edema.
Earnings: Alkermes ( ALKS), GlaxoSmithKline ( GSK), Avanir Pharmaceuticals ( AVNR), Merck ( MRK), Vertex Pharmaceuticals ( VRTX),

Feb. 8:
Adeona Pharmaceuticals ( AEN) investor/analyst day.
Earnings: Seattle Genetics ( SGEN), Rigel Pharmaceuticals ( RIGL), Teva ( TEVA),

Feb. 9:
Earnings: Sanofi-Aventis ( SNY)

Feb. 10:
Earnings: Alexion Pharmaceuticals ( ALXN), Cephalon ( CEPH), Incyte Pharmaceuticals ( INCY), MannKind ( MNKD), Momenta Pharmaceuticals ( NNTA).

Feb 14-15:
BIO CEO & Investor Conference, New York City.

Feb 15:
Expiration of Sanofi-Aventis' $69-a-share tender offer for Genzyme ( GENZ).

Feb. 16:
Earnings: Genzyme

Feb. 17:
Exelixis ( EXEL): Presentation of updated cabozantinib (XL184) data in prostate cancer at ASCO GU symposium
Earnings: Biomarin Pharmaceuticals ( BMRN), Acorda Therapeutics ( ACOR)

Feb. 22:
Earnings: Questcor Pharmaceuticals ( QCOR)

Feb 25:
Pfizer and Protalix Therapeutics ( PLX): FDA approval decision date for Uplyso in Gaucher's disease.

Other potential February events
Idenix Pharmaceuticals ( IDIX): FDA decision on lifting clinical hold on hepatitis C drugs IDX184 and IDX320.
Amylin Pharmaceuticals ( AMLN), Alkermes, Eli Lilly ( LLY): Start of a Bydureon Qt study.

Source: Company reports, BioMedTracker.com

--Written by Adam Feuerstein in Boston.

>To contact the writer of this article, click here: Adam Feuerstein.

>To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein.

>To submit a news tip, send an email to: tips@thestreet.com.
Adam Feuerstein writes regularly for TheStreet.com. In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet.com. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.